MON, JAN 13, 2020 10:30 CET

RLS Global AB received its first order of ChloraSolv for clinical use

During the autumn of 2019, RLS Global focused on the Swedish market with the aim to get ChloraSolv established as a standard product in the regions. In parallel, RLS has worked in close collaboration with OneMed to penetrate the market in municipalities and regions there OneMed has supplier agreements. RLS also has ongoing dialogue with international players in order to establish ChloraSolv in the international market.

RLS Global has now received the first order of ChloraSolv for clinical use. The size of the order is still of minor nature, but it is an important confirmation that the work carried out during the autumn is now showing result.

“We believe that during first half of 2020, RLS Global will receive several positive breakthroughs from the Swedish market as a result of the work that took place during autumn 2019 and is according to plan. At the same time, we have just begun the journey towards achieving our ambition that ChloraSolv is the obvious choice in active debridement of chronic wounds. ChloraSolv will also get the first footprints on the international market during 2020, says Karin Fischer – CEO RLS Global”.

For more information, please contact:
Karin Fischer, CEO RLS Global AB,
+46 (0)702 48 46 51,

Anders Husmark, CBDO RLS Global AB,
+46 (0)72 450 94 03,

This information is information that RLS Global AB (public) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10thof April, 2019, at 08:00.

Press Release